Answers are grounded in this paper and cite their sources.
DILI frequently contributes to the attrition of new drug candidates and is a common cause for the withdrawal of approved drugs from the market. Although some noncytochrome P450 (non-CYP) metabolism enzymes have been implicated in DILI development, their association with DILI outcomes has not been systematically evaluated.
No takes yet. Share an insight, caveat, or question.
Olubamiwa et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: